PECULIARITIES OF EXTERNAL THERAPY OF ATOPIC DERMATITIS IN CHILDREN: ROLE OF METHYLPREDNISOLONE ACEPONATE

The article is dedicated to the issues of external therapy of atopic dermatitis in children. Atopic dermatitis is a chronic allergic inflammatory skin disease; in most cases, it is the first manifestation of atopic march. Timely and adequate pathogenetic external therapy of this disease using topical glucocorticosteroids (TGCSs) helps to quickly and effectively terminate symptoms of the disease and allergic inflammation of the skin. Steroid phobia, which is prevalent among parents of the patients, reduced adherence to the TGCS therapy. The authors analyzed results of the original studies of effectiveness and safety of TGCSs, present general recommendations on TGCS use in children with due regard to morphofunctional peculiarities of children’s skin and clinical‑pharmacological description of the TGCSs featuring the most favorable therapeutic index of 0.1% methylprednisolone aceponate. Methylprednisolone aceponate available in 4 pharmaceutical forms is the optimal drug of choice for atopic dermatitis in children over 4 months of age.

1. Namazova-Baranova L.S., Kulichenko T.V., Borovik T.E., Makarova S.G., Novik G.A., Petrovskii F.I., Vishneva E.A., Alekseeva A.A. Atopicheskii dermatit: rukovodstvo dlya vrachei. Ser. «Bolezni detskogo vozrasta ot A do Ya» [Atopic Dermatitis: a Guide for Physicians.Series "Diseases of Childhood from A to Z"]. Moscow, Pediatr"", 2014. 71 p.

2. Spergel J.M., Paller A.S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003; 112 (Suppl. 6): 118–127.

3. Allergologiya i immunologiya. Pod obshchei red. A.A. Baranova i R.M. Khaitova [Allergy and Immunology. Edited by A.A. Baranov, R.M. Khaitov]. Moscow, Soyuz pediatrov Rossii, 2011. 248 p.

4. Namazova-Baranova L.S. Allergiya u detei: ot teorii k praktike [Allergies in Children: from Theory to Practice]. Moscow, 2010. 668 p

5. Sulzberger M.B., Witten V.H. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952; 19: 101–102.

6. Shakhtmeister I.Ya. Problems in the rational use of medicines outside of glucocorticoid nature in pediatric practice. Detskii doktor = Pediatrician. 1998; 1.

7. Alekseeva A.A., Levina Yu.G., Vishneva E.A., Arshba S.K. Application of topical corticosteroids in the standard regimen of atopic dermatitis in children. Voprosy sovremennoi pediatrii = Current Pediatrics. 2009; 8 (6): 146–150.

8. Atopic Eczema in Children. Management of Atopic Eczema in Children from Birth up to the Age of 12 years. NICE Clinical Guidelines, № 57. London: National Collaborating Centre for Women’s and Children’s Health. 2007. Available at: http://www.nice.org.uk/guidance/CG57

9. Long C.C., Mills C., Finlay A.Y. A practical guide to topical therapy in children. Br J Dermatol. 1998; 138: 293–296.

10. Ersser S., Maguire S., Nicol N. et al. A best practice statement for emollient therapy. Dermatological Nursing. 2007. Р. 1–19.

11. Grebenyuk V.N., Balabolkin I.I. Pediatriya = Pediatrics. 1998; 5: 88–94.

12. Zaumseil R.-P., Fuhrmann H., Kecskes A., Taеuber U., Toеpert M. Methylprednisolone aceponate (Advantan) — an effective topical corticoid therapy with few side effects. Jahrb Dermatol. 1992; 3: 247–263.

13. Luger T.A., Loske K.D., Elsner P., Kapp A., Kescher M., Korting H.C. et al. Topical dermatological therapy with glucocorticoids — therapeutic index. JDDG. 2004; 2: 629–634.

14. Topicheskie steroidy. Advantan. Informatsiya o preparate [Topical Steroids. Advantan. Information about the Drug]. Moscow, 2001.

15. Meffert H., Schuppler J. Methylprednisolone aceponate lotion for treatment of acute eczema. Zeitschrift fur Hautkrankheiten. 1999;74: 88–94.

16. Volkova E.N., Lange D.A., Rodina Yu.A., Tarasova M.V. Methylprednisolone atseponat in the complex therapy of chronic dermatoses: analysis of tactical errors of application. Klinicheskaya dermatologiya i venerologiya = Clinical Dermatology and Venereology. 2010; 5: 84–88.

17. Haria M., Balfour J.A. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother. 1995; 3: 241–253.

18. Giannotti В., Haneke E. Eczema. England. 1995. 74 p.

19. Free C.L., Simon A., Ohlmeyer H. et al. Prevention od stratum corneum lipid phase transitions in vitro by glycerol- an alternative mechanism for skin moisturisation. J Soc Cosmet Chem. 1990; 41: 51–65.

20. Ioffe D.V. Zhiry. V kn.: Khimicheskaya entsiklopediya [Fats. In: Chemical Encyclopedia]. Moscow, Sovetskaya entsiklopediya, 1990. P. 155–157.

21. Nguyen S.H., Dang T.P., Maibach H.I. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol. 2007; 26 (4): 287–292.

22. Mao-Qiang M., Brown B.E., Wu-Pong S. Exogenous Nonphysiologic vs Physiologic Lipids. Arch Dermatol. 1995; 131 (7): 809–816.

23. Fulton J.R. Comedogenicianity di rritancyo f commonluys ed ingredients. J Soc Cosmet Chem. 1989; 4: 321–333.

24. Korsunskaya I.M., Dvoryankova E.V. The role of topical glucocorticosteroid form in achieving optimal treatment effect steroidchuvstvitelnyh dermatoses. Klinicheskaya dermatologiya i venerologiya = Clinical Dermatology and Venereology. 2012; 4: 3.

25. Petrova G.A. Naruzhnaya kortikosteroidnaya terapiya dermatozov [Outdoor Corticosteroid Therapy of Dermatoses]. Nizhny Novgorod, NGMA, 2000.

26. Kubanova A.A., Samsonov V.A., Averbakh E.V. et al. Elokim in treating psoriasis and atopic dermatitis. Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology. 1996; 5: 10–12.

27. Korotkii N.G., Taganov A.V., Shimanovskii N.L. Opyt primeneniya Advantana (metilprednizolona atseponata) v detskoi dermatologicheskoi praktike pri lechenii atopicheskogo dermatita [Experience of Application of Advantan (methylprednisolone atseponat) in Pediatric Dermatology Practice in the Treatment of Atopic Dermatitis]. Moscow, Zhurnal SMU, 2005. P. 3.

28. Bieber T.I., Vick K., Fölster-Holst R., Belloni-Fortina A., Städtler G., Worm M., Arcangeli F. Efficacy and safety of methylprednisolone aceponate ointment 0,1% compared to tacrolimus 0,03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007 Feb; 62 (2): 184–9.

29. Proksch E., Foelster-Holst R., Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci. 2006; 43: 159–169.

30. Mihm M.C., Soter N.A., Dvorak H.F. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol. 1976; 67: 305–312.

31. Wollenberg A., Wen S., Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry. 1999; 37: 147–155.

32. Peserico A., Städtler G., Sebastian M., Suarez Fernandez R., Vick K., Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008; 158: 801–807.